Science Explorer Back to mapMap

Most cited papers from Michalski Huettermann and Partner

What are the most cited papers from Michalski Huettermann and Partner?

The most cited paper from Michalski Huettermann and Partner is "Intellectual property protection" (Ulrich Storz, 2011), with 118 citations. Next come "Pulmonary Artery Banding for Functional Regeneration of End-Stage Dilated Cardiomyopathy in Young Children" (63) and "Rituximab" (41).

Showing 50 of 60 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Intellectual property protection Ulrich Storz · mAbs Open access May 2011 118
2 Pulmonary Artery Banding for Functional Regeneration of End-Stage Dilated Cardiomyopathy in Young Children Dietmar Schranz et al. · Circulation Open access 26 Mar 2018 63
3 Rituximab Ulrich Storz · mAbs Open access 7 May 2014 41
4 Contact-free single-cell cultivation by negative dielectrophoresis Magnus Sebastian Jaeger, Katja Uhlig, Thomas Schnelle et al. · Journal of Physics D Applied Physics 8 Aug 2008 37
5 Antibody-drug conjugates: Intellectual property considerations Ulrich Storz · mAbs Open access 20 Aug 2015 17
6 The patent maze of COVID 19 vaccines Ulrich Storz · Expert Opinion on Therapeutic Patents 18 Jun 2021 15
7 Synthesis and characterization of cBN/WCCo composites obtained by the pulse plasma sintering (PPS) method A. Michalski, Marcin Rosinski, Magdalena Płocińska et al. · IOP Conference Series Materials Science and Engineering Conference paperOpen access 21 Sep 2011 13
8 The COVID-19 vaccine patent race Ulrich Storz · Nature Biotechnology Open access Jul 2022 12
9 Antibody specification beyond the target: claiming a later-generation therapeutic antibody by its target epitope Colin G. Sandercock, Ulrich Storz · Nature Biotechnology Jul 2012 11
10 CRISPR Cas9 − Licensing the unlicensable Ulrich Storz · Journal of Biotechnology 15 Nov 2017 10
11 An update on obtaining and enforcing therapeutic antibody patent claims Theresa Gresl, Ulrich Storz, Colin G. Sandercock · Nature Biotechnology Dec 2016 10
12 The CRISPR Cas patent files, part 1: Cas9 – Where to we stand at the 10 year halftime? Ulrich Storz · Journal of Biotechnology 19 Nov 2023 8
13 Transport of a charge carrier packet in nanoparticulate ZnO electrodes Volker Noack, Horst Weller, Alexander Eychmüller · Physical Chemistry Chemical Physics 2003 8
14 IP Issues of Therapeutic Antibodies Ulrich Storz, Wolfgang Flasche, Johanna Driehaus · SpringerBriefs in biotech patents Book chapter 2012 8
15 IP Issues in the Therapeutic Antibody Industry Ulrich Storz Book chapter 2010 7
16 International intellectual property strategies for therapeutic antibodies Ulrich Storz · mAbs Open access Nov 2011 6
17 Kryptoverwahrung nach dem KWG: Der Versuch einer Konturierung des neuen Erlaubnistatbestands Daniel Resas, Niklas Ulrich, A. de Boer van der Geest · Zeitschrift für Bankrecht und Bankwirtschaft 15 Feb 2020 4
18 A Portfolio Management Approach in Accounts Receivable Management Grzegorz Marek Michalski · South East European Journal of Economics and Business Open access 2008 4
19 Subordination of Shareholder Loans from a Legal and Economic Perspective Martin Gelter, Jürg Roth · RePEc: Research Papers in Economics Open access 2007 4
20 Patent Lifecycle Management, Supplementary Protection Certificates and Data Exclusivity in Biopharmaceutics Ulrich Storz · SpringerBriefs in biotech patents Book chapter 2012 4
21 Redefining antibody patent protection using paratope mapping and CDR-scanning Soma S. R. Banik, Xiaoxiang Deng, Edgar Davidson et al. · Nature Biotechnology Feb 2025 3
22 The CRISPR Cas patent files, part 2: Is Cpf1/Cas12a a less conflict- prone alternative to Cas9? Ulrich Storz · Journal of Biotechnology 3 Jan 2024 3
23 The Cabilly patents Ulrich Storz · mAbs Open access Mar 2012 3
24 Patentability Requirements of Biotech Patents Ulrich Storz · SpringerBriefs in biotech patents Book chapter 19 Nov 2013 3
25 Patents Cannot Be Blamed for Inequitable Access to COVID-19 Vaccines Raildo Duarte, Hasan Irfan Khan, Alejandro Luna et al. · Biotechnology Law Report 25 Mar 2022 2
26 Response to: Dittrich et al.: Non-Embryo-Destructive Extraction of Pluripotent Embryonic Stem Cells – Overlooked Legal Prohibitions, Professional Legal Consequences and Inconsistencies in Patent Law Timo Faltus, Ulrich Storz · Geburtshilfe und Frauenheilkunde Open access 21 Dec 2016 2
27 Patent Landscape in Molecular Diagnostics Ulrich Storz, Wolfgang Flasche, Johanna Driehaus · SpringerBriefs in biotech patents Book chapter 2012 2
28 Peptide Vaccines and Peptide Therapeutics Ulrich Storz, Wolfgang Flasche, Johanna Driehaus · SpringerBriefs in biotech patents Book chapter 2012 2
29 The Limits of Patentability: Stem Cells Ulrich Storz · SpringerBriefs in biotech patents Book chapter 11 Oct 2012 2
30 General Issues of Biotech Patents Andreas Hübel · SpringerBriefs in biotech patents Book chapter 2012 2
31 The complex patent situation regarding antibody Fc engineering Ulrich Storz · Journal of Biotechnology 19 Feb 2026 1
32 The CRISPR Cas patent files, part 3: Prime Editing and integrase-based variants Ulrich Storz · Journal of Biotechnology 15 Jul 2025 1
33 Patent Eligibility of Stem Cells in Europe: Where do we Stand After 8 Years of Case Law? Ulrich Storz, Timo Faltus · Regenerative Medicine 15 Dec 2016 1
34 Practical Aspects of the Preparation and Filing of Patent Applications Fiona G. Bessoth · Methods in molecular biology Book chapter 4 Nov 2012 1
35 Law Enforcement of Biotech Patents Martin Quodbach · SpringerBriefs in biotech patents Book chapter 19 Nov 2013 1
36 Abgabe und Übernahme eines Anteils an einer medizinischen Praxis Eckhard Klapp Book chapter 1997 1
37 Zusammenarbeit zwischen Krankenhäusern und Vertragsärzten – sozialrechtlich erwünscht, berufsrechtlich verboten? Kyrill Makoski · Medizinrecht Jul 2009 1
38 The Limits of Patentability: Genes and Nucleic Acids Aloys Hüttermann · SpringerBriefs in biotech patents Book chapter 11 Oct 2012 1
39 Der Vermögensschaden beim Abrechnungsbetrug Frank Saliger, Michael Tsambikakis · Medizinrecht May 2013 1
40 The Limits of Patentability: Plant Biosciences Andreas Hübel · SpringerBriefs in biotech patents Book chapter 11 Oct 2012 1
41 The CRISPR Cas patent files, part 4: All back to zero, think again! Ulrich Storz · Journal of Biotechnology 23 Aug 2025 0
42 An update on patent issues regarding antibody–drug conjugates Ulrich Storz · Nature Biotechnology Open access May 2026 0
43 VALUE ADD FINANCIAL MEASURES USED BY GERMAN DAX 30 CORPORATIONS AS PART OF HIGHLY PROFESSIONALIZED CORPORATE GOVERNANCE MANAGEMENT Guenter, Grzegorz · DOAJ (DOAJ: Directory of Open Access Journals) Open access 2018 0
44 WITHDRAWN: Moderna’s COVID 19 Patent Under the Magnifying Glass Ulrich Storz · Recent Patents on Biotechnology 17 Jun 2022 0
45 Steuerliche Fragen Eckhard Klapp Book chapter 1997 0
46 Der Praxisübergabevertrag Eckhard Klapp Book chapter 1997 0
47 Checkliste Eckhard Klapp Book chapter 1997 0
48 Einleitung Eckhard Klapp Book chapter 1997 0
49 Intellectual Property in Post-Corona Times: Managing the Future Oliver Baldus, Thomas Heinz Meitinger · American Journal of Industrial and Business Management Open access 2020 0
50 An anisotropic continuum damage model for concrete based on biaxial experiments Alexander Michalski, Michael Brünig · PAMM Dec 2018 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.